Search results for "LIPIDE"

showing 10 items of 532 documents

Study of the antitumor effect of inducible nitric oxide synthase in a breast cancer model : analysis of molecular mechanisms

2013

The anti -tumor effect of a lipid A, OM -174 (lipid portion of LPS) was studied in a model of breast cancer in mice. In vivo, OM- 174 increases the survival of mice whereas in vitro it is not toxic to cancer cells. OM -174 binds to TLR4 immune cells inducing the production of cytokines such as IFNγ. In vitro, the combination of IFNγ to lipid A is cytotoxic. The objective of this thesis is to analyze those molecular mechanisms. We have shown both in vitro and in vivo that the cytotoxicity of the lipid A / IFNγ is dependent of TLR4 and of the receptor for IFNγ, and the NOS II expression. We also showed that the radical species, NO and superoxide anion forming peroxynitrite play a crucial role…

Anti-tumor effectLipid A[SDV.CAN] Life Sciences [q-bio]/CancerMonoxyde d’azoteUbc13NOS II[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyNitric oxideTLR4[SDV.BC] Life Sciences [q-bio]/Cellular BiologyS-nitrosylationEffet anti-tumoralLipide A
researchProduct

Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).

2013

Antitumor activityNeurotransmitter AgentsDrug Industrybusiness.industryChemistrychemistry.chemical_elementNanotechnologyFluorine containingAntineoplastic AgentsGeneral ChemistryFluorineLegislation DrugAntiviral AgentsCommerceAnti-Infective AgentsPharmaceutical PreparationsFluorineHypoglycemic AgentsbusinessGlucocorticoidsPharmaceutical industryHypolipidemic AgentsChemical reviews
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

2020

Several lines of evidence now attest that lipoprotein[a] (Lp[a]) is a significant risk factor for many cardiovascular disorders. This enigmatic lipoprotein, composed of a single copy of apolipoprotein B (apoB) and apolipoprotein[a] (apo [a]), expresses peculiar metabolism, virtually independent from lifestyle interventions. Several therapeutic options have hence been proposed for lowering elevated Lp[a] values, with or without concomitant effect on low density lipoprotein (LDL) particles, mostly encompassing statins, ezetimibe, nicotinic acid, lipoprotein apheresis, and anti-PCSK9 monoclonal antibodies. Since all these medical treatments have some technical and clinical drawbacks, a novel s…

Apolipoprotein Bmedicine.drug_classgovernment.form_of_governmentAntisense therapyHyperlipidemias030204 cardiovascular system & hematologyPharmacologyAntisense therapy; Apolipoprotein[a]; Cardiovascular disease; Lipoprotein[a]Monoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeLipoprotein[a]Internal MedicinemedicineHumans030212 general & internal medicineAntisense therapybiologybusiness.industryLipoprotein(a)Cardiovascular diseaseLipoproteins LDLchemistryConcomitantLow-density lipoproteinBlood Component Removalbiology.proteingovernmentlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein[a]Lipoprotein(a)Lipoproteinmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea.

2016

Obstructive sleep apnea (OSA) is associated with dyslipidemia and increased cardiovascular risk. We assessed the effects of apolipoprotein E ( APOE) genotype on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and lipid subclasses (separated by gradient gel electrophoresis) in patients with OSA. Stable patients (n = 181) prospectively recruited underwent full polysomnography. Both LDL particle size and LDL I proportion were reduced from ∊3∊3 homozygotes to ∊2 carriers and to ∊4 carriers (analysis of variance: P = .024; P = .040, respectively); carriers of the ∊4 allele of the APOE genotype had significantly lower LDL particle size and LDL I proportion compared…

Apolipoprotein EAdultMalemedicine.medical_specialtyGenotypePolysomnographyApolipoprotein E4Statistics as TopicPolysomnography030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInsulin resistanceApolipoproteins EInternal medicineGenotypemedicineHumansGenetic Predisposition to Disease030212 general & internal medicineProspective StudiesParticle SizeAgedSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industryGenetic Carrier ScreeningMiddle Agedmedicine.diseaseObstructive sleep apneaLipoproteins LDLEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAngiology
researchProduct

Serum lipid responses to phytosterol-enriched milk in a moderate hypercholesterolemic population is not affected by apolipoprotein E polymorphism or …

2011

Background/Objectives: The importance of both low-density lipoprotein cholesterol (LDLc) size and the apolipoprotein E (Apo E) in the atherogenic process is known, but there is little information with regard to the effect of phytosterols (PS) on these parameters. The aim of this study was to evaluate the influence of PS on lipid profile and LDLc size according to Apo E genotype. Subjects/Methods: This was a randomized parallel trial employing 75 mild-hypercholesterolemic subjects and consisting of two 3-month intervention phases. After 3 months of receiving a standard healthy diet, subjects were divided into two intervention groups: a diet group (n = 34) and a diet+PS group (n = 41) that re…

Apolipoprotein EMalemedicine.medical_specialtyGenotype030309 nutrition & dieteticsPopulationHypercholesterolemiaMedicine (miscellaneous)030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineApolipoproteins EDouble-Blind MethodInternal medicineHyperlipidemiamedicineAnimalsHumansParticle SizeeducationApolipoprotein e polymorphismTriglycerides0303 health scienceseducation.field_of_studyNutrition and DieteticsPolymorphism GeneticCholesterolPhytosterolCholesterol HDLPhytosterolsCholesterol LDLMiddle Agedmedicine.diseaseLipidsLipoproteins LDLEndocrinologyCholesterolMilkTreatment OutcomechemistryLow-density lipoproteinFood FortifiedFemalelipids (amino acids peptides and proteins)Lipoprotein
researchProduct

Caractérisation des figures myéliniques associées à l'accumulation de lipides polaires induites par différents oxystérols cytotoxiques identifiés dan…

2006

Atherosclerosis is a complex and chronic arterial process which is characterized by a remodeling of the vascular wall, associated with inflammatory reactions, proliferation and cell death process, and with accumulation of oxidized lipids among which oxysterols (cholesterol oxidation products) which might play key roles in the initiation and development of atheromatous lesions. Our work performed on U937 and THP1 promonocytic cells, rat aorta embryonic A7R5 cells, and breast carcinoma MCF7 cells (caspase-3 deficient). Different oxysterols, present in large quantity in atheromatous lesions, were used: 7-cétocholestérol (7KC), 7Β-hydroxycholestérol, 25-hydroxycholestérol, cholestérol-5Α, 6Α-ep…

AthéroscléroseCell DeathApoptose[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyLipidesApoptosisOxystérolsAtherosclerosisLipidsPhospholipidosisPhospholipidose<br />Vitamine-ECaspase-2[ SDV.BBM.BC ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM]Mort cellulaireVitamin E[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM][SDV.BC] Life Sciences [q-bio]/Cellular Biology
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized c…

2016

Background & aims: Inositols are thought to be mediators of the insulin signalling pathway. We assessed the effects of inositols on glycaemic control in fasting and postprandial states and evaluated lipoprotein profile and LDL particle size in healthy population. Methods: A 12-week double-blind clinical trial was performed with forty healthy subjects administered either an inositol-enriched beverage (IEB) -containing 2.23 g of inositols in 250 ml- or a sucrose-sweetened beverage (SB) twice a day. Anthropometric measurements, fasting glucose levels, insulin and HOMA-IR index, lipoprotein profile and postprandial glucose concentrations (measured using the continuous glucose monitoring system …

Blood GlucoseMaleApolipoprotein Bmedicine.medical_treatment030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicinelaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawContinuous glucose monitoring systemHealthy subjects030212 general & internal medicineHypolipidemic AgentsNutrition and DieteticsbiologyArea under the curveFabaceaePostprandial PeriodPostprandialLDL particle sizeSeedsFemaleInositolsAdultmedicine.medical_specialtyCarob pod extractMonitoring AmbulatoryHyperlipidemias03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansHypoglycemic AgentsParticle SizePinitolPlant Extractsbusiness.industryPinitolInsulinMetabolismEndocrinologyLipoproteins IDLchemistrySpainFruitHyperglycemiaDietary Supplementsbiology.proteinInsulin ResistancebusinessInositolLipoproteinClinical Nutrition
researchProduct

Total and Subtypes of Dietary Fat Intake and its Association with Components of the Metabolic Syndrome in a Mediterranean Population at High Cardiova…

2019

Background: The effect of dietary fat intake on the metabolic syndrome (MetS) and in turn on cardiovascular disease (CVD) remains unclear in individuals at high CVD risk. Objective: To assess the association between fat intake and MetS components in an adult Mediterranean population at high CVD risk. Design: Baseline assessment of nutritional adequacy in participants (n = 6560, men and women, 55&ndash

Blood GlucoseMaleMediterranean diethumanosPhysiologyÀcids grassos030204 cardiovascular system & hematologyOverweightDiet Mediterraneanchemistry.chemical_compound0302 clinical medicineRisk Factorsevaluación de riesgosMedicine030212 general & internal medicinemediana edadlípidos2. Zero hungerchemistry.chemical_classificationMetabolic Syndromeeducation.field_of_studyancianoNutrition and Dieteticsdietaresultado del tratamientofood and beveragesMiddle AgedLipidscardiovascular disease risk3. Good healthfat intakeTreatment OutcomeCardiovascular Diseasesdietary fatObesitatFemalemedicine.symptomlcsh:Nutrition. Foods and food supplyPolyunsaturated fatty acidglucosa sanguíneaMediterranean diet cardiovascular disease risk dietary fat fat intake fatty acidsLinoleic acidPopulationdislipidemiasenfermedades cardiovasculareslcsh:TX341-641Risk Assessmentfatty acidsArticle03 medical and health sciencesgrasas dietéticasMediterranean cooking:Ciencias de la Salud::Medicina preventiva [Materias Investigacion]Mediterranean dietCuina mediterràniafactores de riesgoHumansObesitycardiovascular diseaseseducationhiperglucemiaAgedDyslipidemiasbusiness.industryMalalties cardiovascularsHypertriglyceridemiamedicine.diseaseObesityDietary FatsDietCross-Sectional StudieschemistrySpainHyperglycemiaMetabolic syndromebusinessBiomarkersFood Scienceestudios transversalesNutrients
researchProduct